Ads
related to: kappa light chain restriction lymphoma prognosis survival rate- What to Expect
Learn More About What to Expect
From a Hodgkin Lymphoma Treatment.
- Study Results
Visit the Site to Access Clinical
Study Results & Side Effects Info.
- Support & Resources
Explore Support & Resource Info
on a Hodgkin's Treatment Option.
- Pediatric Treatment
Learn More About a Hodgkin Lymphoma
Treatment Option for Your Child.
- What to Expect
Search results
Results From The WOW.Com Content Network
Depending on its phenotype (see above Table), high-count MBL progresses to CLL/SLL, mantel cell lymphoma, follicular lymphoma, splenic marginal zone lymphoma, or splenic lymphoma/leukemia unclassifiable at a rate of 1-2% per year [21] whereas MBL-MZ progresses to a marginal zone B-cell lymphoma, Waldenström's macroglobulinemia, or Hairy cell ...
CD20. Approximately 95% of B-cell lymphomas express CD20, but CD20 is not critical for B-cell survival. Clonal B-cells spontaneously mutate the idiotypic region of their immunoglobulin. This high mutation rate makes them prone to the selection of B-cells lacking the CD20 antigen following treatment with CD20-targeting monoclonal antibodies.
Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa-to-lambda ratio is roughly 2:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. The free light chain ratio ranges from 0.26 to 1.65. [1]
Abnormal free light chain production has also been reported to be prognostic of a worse outcome in multiple myeloma [36] [37] [38] and chronic lymphocytic leukaemia. [39] An abnormal light-chain ratio has been defined as a kappa to lambda chain ratio of less than 0.26 or more than 1.65. [32]
Five-year survival rates for these categories are 87%, 68%, and 36%, respectively. [82] The corresponding median survival rates are 12, 8, and 3.5 years. [83] The International Prognostic Scoring System for Waldenström's Macroglobulinemia has been shown to be reliable. [84] It is also applicable to patients on a rituximab-based treatment ...
Light chain multiple myeloma is diagnosed in patients who have: a) the criteria for diagnosis of multiple myeloma except having a serum free light chain ratio outside the normal range of 0.26 to 1.65 without evidence of an intact immunoglobulin or free heavy chain; or b) an extreme free light chain ratio, i.e. outside the range of 0.02 to 100 ...
Ads
related to: kappa light chain restriction lymphoma prognosis survival rate